Kura Oncology Publishes Ziftomenib Data in Blood
SAN DIEGO, August 10, 2026 Kura Oncology, Inc. announced the publication of new research in Blood detailing the discovery...
AML
Advertisement
Acarix Wins UAE Approval for AI-Powered CADScor System
United Arab Emirates, August 10, 2026 Acarix AB has announced that its CADScor® System, an artificial intelligence-enabled point-of-care diagnostic...
Innovent and Daiichi Sankyo Partner on VANFLYTA in China
SAN FRANCISCO, USA and SUZHOU, China, August 9, 2026 Innovent Biologics and Daiichi Sankyo have entered into an exclusive...
Nabsys Partners With Indiana University on Cancer Genomics
PROVIDENCE, R.I., July 31, 2026 Nabsys 2.0, LLC has entered into a multi-year research collaboration with Indiana University School...
Moleculin Reports Positive Interim MIRACLE Trial Data in Venetoclax-Failed AML Patients
HOUSTON, July 31, 2026 Moleculin Biotech, Inc. announced updated positive preliminary blinded interim results from Part A of its...
Advertisements
Sumitomo Pharma’s Enzomenib Gains FDA Orphan Drug Status for ALL
MARLBOROUGH, Mass., July 30, 2026 Sumitomo Pharma America announced that the U.S. Food and Drug Administration (FDA) has granted...
TScan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial
WALTHAM, Mass., July 29, 2026 TScan Therapeutics announced that the first patient has been dosed with TSC-101 in the...
Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049
CAMBRIDGE, Mass., July 28, 2026 Cullinan Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) following...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
Moleculin Reports Positive MIRACLE Trial Results
HOUSTON, July 6, 2026 Moleculin Biotech announced that Chairman and Chief Executive Officer Walter Klemp discussed encouraging preliminary results...
Advertisement
